Chronic Blood Transfusion Therapy
Treatment for Sickle Cell Disorders
Typical Dosage: Typically 10-20 mL/kg every 3-4 weeks
Effectiveness
88%
Safety Score
55%
Clinical Trials
16
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Typically 10-20 mL/kg every 3-4 weeks
Time to Effect
Immediate for anemia correction, within weeks for clinical stabilization
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
2(Treat 2 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$5,000
Side Effect Mgmt:$3,000
Total Annual:$58,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$64,444
Chronic Blood Transfusion Therapy Outcomes
for Sickle Cell Disorders
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+90%
Common Side Effects
Iron overload (requiring chelation)
+85%
Alloimmunization
+25%
Delayed hemolytic transfusion reactions
+7%
Immediate transfusion reactions
+2%
Active Clinical Trials
2 active trials recruiting for Chronic Blood Transfusion Therapy in Sickle Cell Disorders
A Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease
NCT04166526RECRUITING
8 participants
OBSERVATIONAL
Boston, United States
Started: Oct 25, 2019
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
NCT01499888ACTIVE NOT RECRUITINGPHASE1, PHASE2
45 participants
INTERVENTIONAL
Chicago, United States
Started: Nov 11, 2011
Completed Clinical Trials
13 completed trials for Chronic Blood Transfusion Therapy in Sickle Cell Disorders
Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease - Pilot Intervention Study
NCT00850018COMPLETEDPHASE1
36 participants
INTERVENTIONAL
Oakland, United States +13 more
Started: Dec 1, 2004
Red Blood Cell Survival in Sickle Cell Disease
NCT04426591COMPLETEDPHASE1
22 participants
INTERVENTIONAL
Atlanta, United States +2 more
Started: Oct 29, 2021
Hydroxyurea and Transfusion
NCT03644953COMPLETEDPHASE2
14 participants
INTERVENTIONAL
Washington D.C., United States
Started: Oct 30, 2018
RHD Genotype Matched Red Cells for Anti-D
NCT04156906COMPLETEDEARLY_PHASE1
5 participants
INTERVENTIONAL
Philadelphia, United States
Started: Jul 8, 2020
Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease
NCT01369160COMPLETED
33 participants
OBSERVATIONAL
Atlanta, United States +1 more
Started: May 1, 2005
Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization.
NCT03111589COMPLETEDNA
102 participants
INTERVENTIONAL
Brussels, Belgium +1 more
Started: Oct 1, 2016
Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease
NCT04606160COMPLETEDNA
20 participants
INTERVENTIONAL
Dallas, United States
Started: Dec 9, 2020
Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport
NCT00246077COMPLETED
5 participants
OBSERVATIONAL
Kansas City, United States
Started: Oct 1, 2005
The Radiofrequency Therapy in Management of Sickle Cell Disease Chronic Pain RCT Tested the Effect of TECAR Therapy on Sickle Cell Disease Chronic Pain.
NCT07066072COMPLETEDNA
170 participants
INTERVENTIONAL
Cairo, Egypt
Started: Dec 1, 2022
Sickle Cell Disease (SCD) Decision Aid
NCT03224429COMPLETEDNA
222 participants
INTERVENTIONAL
Started: May 15, 2014
Decision Aid for Therapeutic Options In Sickle Cell Disease
NCT02326597COMPLETEDNA
134 participants
INTERVENTIONAL
Atlanta, United States
Started: Jan 1, 2015
Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia
NCT03715972COMPLETED
165 participants
OBSERVATIONAL
Los Angeles, United States
Started: Jul 15, 2018
Long Term Effects of Erythrocyte Lysis
NCT00842621COMPLETED
390 participants
OBSERVATIONAL
Memphis, United States
Started: Mar 1, 2009